Search Result

Results for "

hyperplasia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (9) Adrenergic Receptor (32) Akt (2) AMPK (1) Androgen Receptor (3) Angiotensin Receptor (3) Apoptosis (6) Bacterial (2) Biochemical Assay Reagents (1) Calcium Channel (1) CFTR (5) CRFR (1) Endogenous Metabolite (9) Endothelin Receptor (2) Epigenetic Reader Domain (1) Fungal (1) GnRH Receptor (1) Histamine Receptor (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (10) Keap1-Nrf2 (1) LPL Receptor (1) MAPKAPK2 (MK2) (1) MMP (1) Parasite (1) Phosphodiesterase (PDE) (1) PI3K (1) Pyruvate Kinase (2) Raf (1) Reactive Oxygen Species (1) Serotonin Transporter (4) STAT (1) TGF-β Receptor (1) TNF Receptor (1)
By Research Areas:	Cancer (29) Cardiovascular Disease (15) Endocrinology (37) Infection (1) Inflammation/Immunology (6) Metabolic Disease (14) Neurological Disease (11)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113405

21-Deoxycortisol	Endogenous Metabolite	Endocrinology
21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Cancer
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research . Crinecerfont (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

HY-106203C

Crinecerfont tosylate	CFTR	Metabolic Disease
Crinecerfont tosylate is an effective orally active antagonist of the CRF1 receptor. Crinecerfont tosylate can be used in research on congenital adrenal hyperplasia (CAH) .

HY-156522

CRF1 receptor antagonist-1	CFTR	Endocrinology
CRF1 receptor antagonist-1 (Compound 2) is a CRF1 receptor antagonist. CRF1 receptor antagonist-1 can be used for research of congenital adrenal hyperplasia (CAH) .

HY-105537

Ro 70‐0004 RS-100975	Adrenergic Receptor	Endocrinology
Ro 70-0004 (RS-100975) is a selective alpha1A-adrenoceptor antagonist with a pK_i of 8.9. Ro 70‐0004 can be used in the study of prostatic hyperplasia .

HY-113405R

21-Deoxycortisol (Standard)	Endogenous Metabolite	Endocrinology
21-Deoxycortisol (Standard) is the analytical standard of 21-Deoxycortisol. This product is intended for research and analytical applications. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-123323

MK-0434	5 alpha Reductase	Endocrinology
MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia .

HY-106203

Crinecerfont SSR-125543	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-101826A

ER21355 hydrochloride	Phosphodiesterase (PDE)	Cancer
ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .

HY-B0391B

Naftopidil hydrochloride KT-611 hydrochloride; BM-15275 hydrochloride	Adrenergic Receptor	Cancer
Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia .

HY-B0391A

Naftopidil dihydrochloride KT-611 dihydrochloride; BM-15275 dihydrochloride	Adrenergic Receptor	Cancer
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia .

HY-B0391

Naftopidil KT-611; BM-15275	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

HY-P3501

Fexapotide NX-1207 free acid	Apoptosis	Cancer
Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-P3501A

Fexapotide TFA NX-1207 TFA	Apoptosis	Cancer
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-122237

ATZ-1993	Endothelin Receptor	Cardiovascular Disease
ATZ-1993 is an orally active, nonpeptide endothelin receptor subtype Aand endothelin receptor subtype B antagonist with pK_i values of 8.69, 7.20, respectively. ATZ-1993 has the potential for the research of intimal hyperplasia after balloon denudation of the carotid artery .

HY-P3412

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

HY-B0371F

Terazosin hydrochloride Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371

Terazosin	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0391R

Naftopidil (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (Standard) is the analytical standard of Naftopidil. This product is intended for research and analytical applications. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

HY-B0661R

Tamsulosin (Standard)	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology Cancer
Tamsulosin (Standard) is the analytical standard of Tamsulosin. This product is intended for research and analytical applications. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-107637

ONO-4817	MMP	Cardiovascular Disease
ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .

HY-116379

RS-100329	Adrenergic Receptor	Metabolic Disease
RS-100329 is an α1-adrenergic receptor (α1-AR) antagonist that effectively inhibits α1-adrenergic receptor-mediated contractions of lower urinary tract tissues in vitro and in vivo. RS-100329 can be used in the research of symptoms related to benign prostatic hyperplasia .

HY-B0371A

Terazosin hydrochloride dihydrate Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0661

Tamsulosin (R)-(-)-YM12617 free base; LY253351 free base	Adrenergic Receptor Apoptosis	Neurological Disease Endocrinology Cancer
Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-B0661A

Tamsulosin hydrochloride (R)-(-)-YM12617; LY253351	Adrenergic Receptor Apoptosis	Neurological Disease Endocrinology Cancer
Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-107385

Epristeride 1 Publications Verification ONO-9302; SKF105657	5 alpha Reductase	Cancer
Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with K_i value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .

HY-N8850

Angelol G	Others	Cancer
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-B0371FR

Terazosin (hydrochloride) (Standard)	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-13635A

Finasteride acetate MK-906 acetate	5 alpha Reductase	Cancer
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-B0371AR

Terazosin (hydrochloride dihydrate) (Standard)	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-13635

Finasteride 4 Publications Verification MK-906	5 alpha Reductase	Cancer
Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-107385R

Epristeride (Standard)	5 alpha Reductase	Cancer
Epristeride (Standard) is the analytical standard of Epristeride. This product is intended for research and analytical applications. Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with K_i value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .

HY-106203B

(R)-Crinecerfont (R)-SSR-125543	CFTR	Metabolic Disease
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-103204

RS100329 hydrochloride	Adrenergic Receptor	Endocrinology
RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pK_i values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .

HY-106761

Oxodipine	Calcium Channel	Cardiovascular Disease Others
Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC₅₀ of 0.24 μM, and against T-type Ca currents (I) with an IC₅₀ of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-113405S1

21-Deoxycortisol-d8	Isotope-Labeled Compounds Endogenous Metabolite	Endocrinology
21-Deoxycortisol-d₈ is the deuterium labeled 21-Deoxycortisol. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia[1].

HY-165123

Mepartricin	Fungal Parasite	Infection
Mepartricin is a polyene macrolide with antifungal and antiprotozoal activities, widely used in research related to benign prostatic hyperplasia .

HY-B0192AS1

Alfuzosin-d7 hydrochloride SL 77499-10-d₇	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192AS

Alfuzosin-d3 hydrochloride SL 77499-10-d₃	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-123710

GYKI-16084	Endogenous Metabolite	Others
GYKI-16084 is a new compound that can be isolated from dog and rat urine. GYKI-16084 can be used in the research of benign prostatic hyperplasia .

HY-B0391S1

Naftopidil-d5 KT-611-d₅; BM-15275-d₅	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-19144

ONO-3805	5 alpha Reductase	Others
ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.

HY-P2563

[Tyr(P)4] Angiotensin II	Angiotensin Receptor	Metabolic Disease
[Tyr(P)4] Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels .

HY-P1564

[Sar1, Ile8]-Angiotensin II	Angiotensin Receptor	Cardiovascular Disease Endocrinology
[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

HY-P1564A

[Sar1, Ile8]-Angiotensin II TFA AngiotensinII TFA; Angiotensin 2 TFA	Angiotensin Receptor	Others
[Sar1, Ile8]-Angiotensin II (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

HY-N8856

Angelol M	Others	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P3412

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

HY-P1564A

[Sar1, Ile8]-Angiotensin II TFA AngiotensinII TFA; Angiotensin 2 TFA	Angiotensin Receptor	Others
[Sar1, Ile8]-Angiotensin II (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

HY-P3501

Fexapotide NX-1207 free acid	Apoptosis	Cancer
Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-P2563

[Tyr(P)4] Angiotensin II	Angiotensin Receptor	Metabolic Disease
[Tyr(P)4] Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels .

HY-P1564

[Sar1, Ile8]-Angiotensin II	Angiotensin Receptor	Cardiovascular Disease Endocrinology
[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-P9934

Abciximab C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113405

21-Deoxycortisol	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology Steroids	Endogenous Metabolite
21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-B0661

Tamsulosin (R)-(-)-YM12617 free base; LY253351 free base	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Endocrinology Cancer	Adrenergic Receptor Apoptosis
Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-B0661A

Tamsulosin hydrochloride (R)-(-)-YM12617; LY253351	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Adrenergic Receptor Apoptosis
Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-113405R

21-Deoxycortisol (Standard)	Structural Classification Source classification Endogenous metabolite Steroids	Endogenous Metabolite
21-Deoxycortisol (Standard) is the analytical standard of 21-Deoxycortisol. This product is intended for research and analytical applications. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-B0371

Terazosin	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0661R

Tamsulosin (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Adrenergic Receptor Endogenous Metabolite
Tamsulosin (Standard) is the analytical standard of Tamsulosin. This product is intended for research and analytical applications. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-N8850

Angelol G	Structural Classification Leguminosae Campylotropis hirtella (Franch.) Schindl. Source classification Coumarins Phenylpropanoids Plants	Others
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-N8856

Angelol M	Structural Classification Leguminosae Campylotropis hirtella (Franch.) Schindl. Source classification Coumarins Phenylpropanoids Plants	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-B0661AR

Tamsulosin (hydrochloride) (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Adrenergic Receptor Apoptosis
Tamsulosin (hydrochloride) (Standard) is the analytical standard of Tamsulosin hydrochloride (HY-B0661A). Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-N13195

(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	5 alpha Reductase
(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC₅₀ value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness .

HY-N0448

10-Gingerol 2 Publications Verification	Zingiber officinale Roscoe Structural Classification Natural Products Monophenols Classification of Application Fields Source classification Phenols Plants Inflammation/Immunology Disease Research Fields Zingiberaceae	AMPK Reactive Oxygen Species Akt PI3K Interleukin Related TNF Receptor Apoptosis
10-Gingerol is an AMPK agonist, which is found in the ginger oleoresin from fresh rhizome with anti-inflammatory, antioxidant and anti-proliferative activities. 10-Gingerol suppresses neointimal hyperplasia and inhibits vascular smooth muscle cell proliferation. 10-Gingerol exhibits substantial scavenging activities with an IC₅₀ value of 10.47 μM against DPPH radical, an IC₅₀ value of 1.68 μM against superoxide radical and an IC₅₀ value of 1.35 μM against hydroxyl radical. 10-Gingerol inhibits the proliferation of MDA-MB-231 tumor cell line with an IC₅₀ of 12.1 μM. 10-Gingerol suppresses the proliferation, migration, invasion, and induced apoptosis through targeting the PI3K/Akt signaling pathway in MDA-MB-231/IR cells. 10-Gingerol is promising for research of ulcerative colitis .

Cat. No.	Product Name	Chemical Structure

HY-113405S1

21-Deoxycortisol-d8
21-Deoxycortisol-d₈ is the deuterium labeled 21-Deoxycortisol. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia[1].

HY-B0192AS1

Alfuzosin-d7 hydrochloride
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192AS

Alfuzosin-d3 hydrochloride
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0391S1

Naftopidil-d5
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-B0661AS1

Tamsulosin-d4 hydrochloride
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0661AS

Tamsulosin-d5 hydrochloride
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-B0192S

Alfuzosin-d7
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-B0661S

Tamsulosin-d4
Tamsulosin-d₄ ((R)-(-)-YM12617 (free base)-d₄) is deuterium labeled Tamsulosin. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-B0192S3

Alfuzosin-d6
Alfuzosin-d₆ (SL 77499-d₆) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-13635S

Finasteride-d9

Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

Cat. No.	Product Name		Classification